Faisal Mahmood

Dr. Faisal Mahmood

Department of Infectious Disease, Yunnan University, Kunming, Yunnan, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 December 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
RXRuixian Xu
Ruixian Xu
MAMaher Un Nisa Awan
Maher Un Nisa Awan
YSYuzhu Song
Yuzhu Song
QHQinqin Han
Qinqin Han
JZJinyang Zhang
Jinyang Zhang
Hepatitis B virus (HBV) infection is a global public health problem that is closely related to liver cirrhosis and hepatocellular carcinoma (HCC). The prevalence of acute and chronic HBV infection, liver cirrhosis, and HCC has significantly decreased as a result of the introduction of universal HBV vaccination programs. The first hepatitis B vaccine approved was developed by purifying the hepatitis B surface antigen (HBsAg) from the plasma of asymptomatic HBsAg carriers. Subsequently, recombinant DNA technology led to the development of the recombinant hepatitis B vaccine. Although there are already several licensed vaccines available for HBV infection, continuous research is essential to develop even more effective vaccines. Prophylactic hepatitis B vaccination has been important in the prevention of hepatitis B because it has effectively produced protective immunity against hepatitis B viral infection. Prophylactic vaccines only need to provoke neutralizing antibodies directed against the HBV envelop proteins, whereas therapeutic vaccines are most likely needed to induce a comprehensive T cell response and thus, should include other HBV antigens, such as HBV core and polymerase. The existing vaccines have proven to be highly effective in preventing HBV infection, but ongoing research aims to improve their efficacy, duration of protection, and accessibility. The routine administration of the HBV vaccine is safe and well-tolerated worldwide. The purpose of this type of immunization is to trigger an immunological response in the host, which will halt HBV replication. The clinical efficacy and safety of the HBV vaccine are affected by a number of immunological and clinical factors. However, this success is now in jeopardy due to the breakthrough infections caused by HBV variants with mutations in the S gene, high viral loads, and virus-induced immunosuppression. In this review, we describe various types of available HBV vaccines, along with the recent progress in the ongoing battle to develop new vaccines against HBV.

1 November 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
RXRuixian Xu
Ruixian Xu
MAMaher Un Nisa Awan
Maher Un Nisa Awan
YSYuzhu Song
Yuzhu Song
QHQinqin Han
Qinqin Han
JZJinyang Zhang
Jinyang Zhang
The catalysis of disulphide (SS) bonds is the most important characteristic of protein disulphide isomerase (PDI) family. Catalysis occurs in the endoplasmic reticulum, which contains many proteins, most of which are secretory in nature and that have at least one s-s bond. Protein disulphide isomerase A3 (PDIA3) is a member of the PDI family that acts as a chaperone. PDIA3 is highly expressed in response to cellular stress, and also intercept the apoptotic cellular death related to endoplasmic reticulum (ER) stress, and protein misfolding. PDIA3 expression is elevated in almost 70% of cancers and its expression has been linked with overall low cell invasiveness, survival and metastasis. Viral diseases present a significant public health threat. The presence of PDIA3 on the cell surface helps different viruses to enter the cells and also helps in replication. Therefore, inhibitors of PDIA3 have great potential to interfere with viral infections. In this review, we summarize what is known about the basic structure, functions and role of PDIA3 in viral infections. The review will inspire studies of pathogenic mechanisms and drug targeting to counter viral diseases.

6 May 2022 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
MAMaher Un Nisa Awan
Maher Un Nisa Awan
FYFang Yan
Fang Yan
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
LBLiping Bai
Liping Bai
JLJingyu Liu
Jingyu Liu
JBJie Bai
Jie Bai
Significance: Thioredoxin 1 (Trx1) is a ubiquitous protein that is found in organisms ranging from prokaryotes to eukaryotes. Trx1 acts as reductases in redox regulation and protects proteins from oxidative aggregation and inactivation. Trx1 helps the cells to cope with various environmental stresses and inhibits programmed cell death. It is beneficial to neuroregeneration and resistance against oxidative stress-associated neuron damage. Trx1 also plays important roles in suppressing neurodegenerative disorders. Recent Advances: Trx1 is a redox regulating protein involved in neuronal protection. According to a previous study, Trx1 expression is increased by nerve growth factor (NGF) and necessary for neurite outgrowth of PC12 cells. Trx1 has been shown to promote the growth of neurons. Trx1 knockout or knockdown has the worse impact on cell viability and survival. Critical Issues: Trx1 has functions in central nervous system. Trx1 plays the defensive roles against oxidative stress in neurodegenerative diseases. Future Directions: In this review, we focus on the structure of Trx1 and basic functions of Trx1. Trx1 plays a neuroprotective role by suppressing endoplasmic reticulum stress in Parkinson's disease. Neurodegenerative diseases have no cure and carry a high cost to the health care system and patient's families. Trx1 may be taken as a new target for neurodegenerative disorder therapy. Further studies of the Trx1 roles and mechanisms on neurodegenerative diseases are needed. Antioxid. Redox Signal. 36, 1023–1036.

14 October 2025 in Journal of Soil Science and Plant Nutrition
Verified
Journal Article
Closed access
PDF file
Ghulam MurtazaGhulam Murtaza
Ghulam Murtaza
MJMuhammad Bilawal Junaid
Muhammad Bilawal Junaid
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
MUMuhammad Usman
Muhammad Usman
Muhammad AzamMuhammad Azam
Muhammad Azam
RIRashid Iqbal
Rashid Iqbal

18 May 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
RXRuixian Xu
Ruixian Xu
MAMaher Un Nisa Awan
Maher Un Nisa Awan
TJTing Jia
Ting Jia
TZTaoping Zhang
Taoping Zhang
JZJinyang Zhang
Jinyang Zhang
More than 250 million people worldwide have chronic hepatitis B virus (HBV) infections, resulting in over 1 million annual fatalities because HBV cannot be adequately treated with current antivirals. Hepatocellular carcinoma (HCC) risk is elevated in the presence of the HBV. Novel and powerful medications that specifically target the persistent viral components are needed to remove infection. This study aimed to use HepG2.2.15 cells and the rAAV-HBV1.3 C57BL/6 mouse model established in our laboratory to examine the effects of 16F16 on HBV. The transcriptome analysis of the samples was performed to examine the impact of 16F16 therapy on host factors. We found that the HBsAg and HBeAg levels significantly decreased in a dose-dependent manner following the 16F16 treatment. 16F16 also showed significant anti-hepatitis B effects in vivo. The transcriptome analysis showed that 16F16 regulated the expression of several proteins in HBV-producing HepG2.2.15 cells. As one of the differentially expressed genes, the role of S100A3 in the anti-hepatitis B process of 16F16 was further investigated. The expression of the S100A3 protein significantly decreased following the 16F16 therapy. And upregulation of S100A3 caused an upregulation of HBV DNA, HBsAg, and HBeAg in HepG2.2.15 cells. Similarly, knockdown of S100A3 significantly reduced the levels of HBsAg, HBeAg, and HBV DNA. Our findings proved that S100A3 might be a new target for combating HBV pathogenesis. 16F16 can target several proteins involved in HBV pathogenesis, and may be a promising drug precursor molecule for the treatment of HBV.

17 February 2025 in International Journal of Applied and Experimental Biology
Verified
Journal Article
Open access
PDF file
TPTing Pu
Ting Pu
MJMuhammad Ameen Jamal
Muhammad Ameen Jamal
MTMuhammad Nauman Tahir
Muhammad Nauman Tahir
SUSalman Ullah
Salman Ullah
MAMaher Un Nisa Awan
Maher Un Nisa Awan
Faisal MahmoodFaisal Mahmood
Faisal Mahmood
Hyperhidrosis, a condition of excessive sweat generation, is believed to be genetic, but it is yet not known well whether primary hyperhidrosis is regulated by a single gene or multiple genes. The prospective genes that regulate primary hyperhidrosis are known to be ITPR2, TMEM16A, FOXA1 and AQP5. Of these four genes, ITPR2 gene plays a significant role in primary hyperhidrosis; thus in the current research sequence, analysis of this gene was carried out. Following inclusion and exclusion criteria, whole blood samples were taken from four patients inflicted with primary hyperhidrosis and two from healthy persons as control. From the blood samples, white blood cells were separated by reacting the samples with ammonium chloride (NH4Cl) solution to lyse red blood cells. Then total RNA was extracted using the trizol reagent. For synthesizing cDNA, one script reverse transcriptase cDNA synthesis kit was employed. The cDNA samples were quantified using a Qubit Flourometer and their quality was appraised on agarose gel. Real time PCR was performed to carry out the quantitative analysis of these four genes. Of four genes, the expression of three genes, i.e., TMEM16A, ITPR2 and FOXA1, was found to be significantly high in the primary hyperhidrosis patients, whereas low expression of the gene AQP5 was noted compared to that of the control samples. Microarray data analysis on anhidrosis was done using GEO2R database as well as the anhidrosis datasets available on Gene Exression Omnibus (GEO). From this analysis, the low expression of FOXA1 in anhidrosis was confirmed. Based on the highest expression of ITPR2 in hyperhidrosis, it was selected for PCR amplification as well as sequencing. The sequence analysis of ITPR2 showed 100% identity without any mutation.These key genes will further help us to devise new treatment modalities.